NAFLD / NASH as a Metabolic Disease: Improving Patients Outcomes – Part 2

Prof. A.G.(Onno) Holleboom, Netherlands, discusses non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as a metabolic disease and reviews management strategies in order to improve patients outcomes.
Play Video

Prof. A.G.(Onno) Holleboom, Netherlands, discusses the spectrum of NAFLD, where he presents a snapshot of the relative damages and repairs which focus on the NAFLD field in 2022. He then discusses the hepatic component metabolic syndrome (MetSy) and the mechanisms and pharmacological developments on NAFLD / NASH. For the clinicians he presents various statistics that summarise NAFLD / NASH as an ever more prevalent and severe liver disease.

Prof. A.G.(Onno) Holleboom

Prof. A.G.(Onno) Holleboom

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates